Who are hypertonic saline mixed Dextran's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Balanced crystalloid, Dextrose 5% in water (D5W), Isotonic crystalloids, preservative-free 0.9% saline..

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hypertonic-saline-mixed-dextran.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

hypertonic saline mixed Dextran — Competitive Intelligence Brief

hypertonic saline mixed Dextran (hypertonic saline mixed Dextran) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Crystalloid solution. Area: Critical Care.

phase 3 Crystalloid solution Critical Care Biologic Live · refreshed every 30 min

Target snapshot

hypertonic saline mixed Dextran (hypertonic saline mixed Dextran) — Sunnybrook Health Sciences Centre. Hypertonic saline mixed Dextran works by increasing blood volume and improving blood flow to vital organs.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
hypertonic saline mixed Dextran TARGET	hypertonic saline mixed Dextran	Sunnybrook Health Sciences Centre	phase 3	Crystalloid solution
Balanced crystalloid	Balanced crystalloid	National Taiwan University Hospital	marketed	Intravenous fluid / Crystalloid solution
Dextrose 5% in water (D5W)	Dextrose 5% in water (D5W)	Hospital for Special Surgery, New York	marketed	Intravenous fluid / Crystalloid solution
Isotonic crystalloids	Isotonic crystalloids	Marie Kristine Jessen, MD	marketed	Intravenous fluid / Crystalloid solution
preservative-free 0.9% saline.	preservative-free 0.9% saline.	Al-Azhar University	phase 3	Crystalloid solution

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Crystalloid solution class)

Al-Azhar University · 1 drug in this class
Sunnybrook Health Sciences Centre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). hypertonic saline mixed Dextran — Competitive Intelligence Brief. https://druglandscape.com/ci/hypertonic-saline-mixed-dextran. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab